A Phase Iia Prospective, Open-label, Multicenter Study To Determine The Pharmacokinetics (pk) And Safety And Tolerability Of Aztreonam-avibactam (Atm-avi) For The Treatment Of Complicated Intra-abdominal Infections (Ciais) In Hospitalized Adults
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Avibactam/aztreonam (Primary) ; Metronidazole
- Indications Intra-abdominal infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms REJUVENATE
- Sponsors AstraZeneca; Pfizer
- 16 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
- 16 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Nov 2017.
- 16 Dec 2016 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.